Results of Entitlement Offer
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The allotment of new shares and options is scheduled for mid-April, with trading expected to commence shortly thereafter. Percheron plans to present data from its phase I clinical trial at upcoming major oncology conferences.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Prospectus - Non-renounceable Entitlement Offer
- Non-renounceable Entitlement Offer
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities Report and Appendix 4C
Later from Percheron Therapeutics
- Percheron Therapeutics Announces CEO Succession
- Notice of date of AGM and other relevant dates
- Application for quotation of securities - PER
- Appendix 4E and Annual Report
- Appendix 4G and Corporate Governance Statement
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics